• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

    3/29/22 4:23:51 PM ET
    $SRRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRRA alert in real time by email
    SC 13G/A 1 d308257dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Sierra Oncology, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    82640U404

    (CUSIP Number)

    March 24, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Frazier Life Sciences VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      522,663 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      522,663 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      522,663 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 522,663 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHM Life Sciences VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      522,663 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      522,663 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      522,663 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 522,663 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHM Life Sciences VIII, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      522,663 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      522,663 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      522,663 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 522,663 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Frazier Healthcare VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHM VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHM VI, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Frazier Life Sciences Public Fund, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      1,789,535 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      1,789,535 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,789,535 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      7.6% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      1,789,535 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      1,789,535 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,789,535 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      7.6% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      1,789,535 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      1,789,535 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,789,535 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      7.6% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      James N. Topper

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      2,366,853 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      2,366,853 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,366,853 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      10.0% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 522,663 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P., 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. and 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. James N. Topper, Patrick J. Heron, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Patrick J. Heron

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      2,366,853 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      2,366,853 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,366,853 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      10.0% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 522,663 shares of Common Stock held directly by Frazier Life Sciences VIII, L.P., 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. and 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. James N. Topper and Patrick J. Heron are the sole members of FHM Life Sciences VIII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences VIII, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. James N. Topper, Patrick J. Heron, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Alan Frazier

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Nader Naini

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Nathan Every

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      54,655 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      54,655 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      54,655 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      0.2% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 54,655 shares of Common Stock held directly by Frazier Healthcare VI, L.P. FHM VI, L.P. is the general partner of Frazier Healthcare VI, L.P. and FHM VI, L.L.C. is the general partner of FHM VI, L.P. James N. Topper, Patrick J. Heron, Alan Frazier, Nader Naini and Nathan Every are the members of FHM VI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VI, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      Albert Cha

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      1,789,535 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      1,789,535 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,789,535 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      7.6% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    CUSIP No. 82640U404

     

      1.    

      Names of Reporting Persons

     

      James Brush

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0 shares

       6.  

      Shared Voting Power

     

      1,789,535 shares (1)

       7.  

      Sole Dispositive Power

     

      0 shares

       8.  

      Shared Dispositive Power

     

      1,789,535 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,789,535 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      7.6% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,789,535 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on 23,665,100 shares of Common Stock outstanding on March 7, 2022 as set forth in the Issuer’s Form 10-K filed with the SEC on March 10, 2022.


    Item 1(a).

    Name of Issuer: Sierra Oncology, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices: 1820 Gateway Drive, San Mateo, CA, 94404.

     

    Item 2(a).

    Name of Person Filing:

    The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

    Frazier Life Sciences VIII, L.P. (“FLS VIII”)

    FHM Life Sciences VIII, L.P. (“FHM VIII L.P.”)

    FHM Life Sciences VIII, L.L.C. (“FHM VIII L.L.C.”)

    Frazier Healthcare VI, L.P. (“FH VI”)

    FHM VI, L.P.

    FHM VI, L.L.C.

    Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    James N. Topper (“Topper”)

    Patrick J. Heron (“Heron”)

    Alan Frazier (“Frazier”)

    Nader Naini (“Naini”)

    Nathan Every (“Every”)

    Albert Cha (“Cha”)

    James Brush (“Brush” and together with Topper, Heron, Frazier, Naini, Every and Cha, the “Members”)

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The address and principal business office of the Reporting Persons is:

    c/o Frazier Healthcare Partners

    601 Union Street, Suite 3200

    Seattle, Washington 98101

     

    Item 2(c).

    Citizenship:

     

    Entities:    FLS VIII    -    Delaware, U.S.A.
       FHM VIII L.P.    -    Delaware, U.S.A.
       FHM VIII L.L.C.    -    Delaware, U.S.A.
       FH VI    -    Delaware, U.S.A.
       FHM VI, L.P.    -    Delaware, U.S.A.
       FHM VI, L.L.C.    -    Delaware, U.S.A.
       FLSPF    -    Delaware, U.S.A.
       FHMLSP, L.P.    -    Delaware, U.S.A.
       FHMLSP, L.L.C.    -    Delaware, U.S.A.
    Individuals:    Topper    -    United States Citizen
       Heron    -    United States Citizen
       Frazier    -    United States Citizen
       Naini    -    United States Citizen
       Every    -    United States Citizen
       Cha    -    United States Citizen
       Brush    -    United States Citizen

     

    Item 2(d).

    Title of Class of Securities: Common Stock

     

    Item 2(e).

    CUSIP Number: 82640U404

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c)    ☐ Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
    (d)    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐ A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)    ☐ Group, in accordance with §240.13d–1(b)(1)(ii)(K).
       If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a)

    Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

     

      (b)

    Percent of Class: See Row 11 of cover page for each Reporting Person

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

     

      (ii)

    Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Each member of the group is identified on the signature page to this Schedule 13G amendment.

     

    Item 9.

    Notice of Dissolution of a Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 29, 2022     FRAZIER LIFE SCIENCES VIII, L.P.
        By FHM Life Sciences VIII, L.P., its general partner
        By FHM Life Sciences VIII, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FHM LIFE SCIENCES VIII, L.P.
        By FHM Life Sciences VIII, L.L.C., its general partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FHM LIFE SCIENCES VIII, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FRAZIER HEALTHCARE VI, L.P.
        By: FHM VI, L.P., its General Partner
        By: FHM VI, LLC, its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FHM VI, L.P.
        By: FHM VI, LLC, its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FHM VI, LLC
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
        By: FHMLSP, L.P., its General Partner
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer


    Date: March 29, 2022     FHMLSP, L.P.
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     FHMLSP, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: March 29, 2022     By:  

    *

          James N. Topper
    Date: March 29, 2022     By:  

    *

          Patrick J. Heron
    Date: March 29, 2022     By:  

    *

          Alan Frazier
    Date: March 29, 2022     By:  

    *

          Nader Naini
    Date: March 29, 2022     By:  

    *

          Nathan Every
    Date: March 29, 2022     By:  

    **

          Albert Cha
    Date: March 29, 2022     By:  

    **

          James Brush
    Date: March 29, 2022     By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, as Attorney-in-Fact

     

    *

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on February 24, 2017.

    **

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

    Get the next $SRRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRRA

    DatePrice TargetRatingAnalyst
    1/31/2022$35.00 → $51.00Buy
    HC Wainwright & Co.
    11/30/2021$33.00 → $39.00Overweight
    Cantor Fitzgerald
    11/5/2021$29.00 → $35.00Buy
    HC Wainwright & Co.
    9/27/2021$33.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SRRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

      – Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. "Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team designed a targeted study to address the highest unmet need and delivered incredible results in the midst of a pandemic. We are thrilled to submit this ND

      6/17/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

      – Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also present with thrombocytopenia – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi

      5/12/22 10:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Codexis Announces CEO Transition Effective August 9, 2022

      Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad

      7/18/22 4:05:00 PM ET
      $CDXS
      $SRRA
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

      RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze

      4/25/22 8:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in

      11/10/21 4:15:00 PM ET
      $ORIC
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/11/22 4:30:36 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)

      SC 13G/A - Sierra Oncology, Inc. (0001290149) (Subject)

      7/5/22 5:06:15 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)

      SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)

      5/6/22 4:33:35 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Sierra Oncology Inc.

      15-12G - Sierra Oncology, Inc. (0001290149) (Filer)

      7/11/22 4:01:52 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:18 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sierra Oncology Inc.

      EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)

      7/8/22 12:15:23 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $51.00 from $35.00 previously

      1/31/22 9:32:16 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Sierra Oncology with a new price target

      Cantor Fitzgerald reiterated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $39.00 from $33.00 previously

      11/30/21 8:05:31 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sierra Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $35.00 from $29.00 previously

      11/5/21 12:45:48 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Financials

    Live finance-specific insights

    See more
    • Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

      —New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpoints. "These data are extremely exciting and everything we had hoped to see from the trial," said Step

      1/25/22 7:00:00 AM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

       —Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings

      8/5/21 4:05:00 PM ET
      $AZN
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Vivo Opportunity, Llc returned $183,123,160 worth of shares to the company (3,329,512 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:59:45 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Orbimed Advisors Llc returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:50:05 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ashiya Mona returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)

      4 - Sierra Oncology, Inc. (0001290149) (Issuer)

      7/1/22 4:46:16 PM ET
      $SRRA
      Biotechnology: Pharmaceutical Preparations
      Health Care